Lymphoma / 2013 / Article / Fig 2

Research Article

Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

Figure 2

Cytomorphology of therapy-resistant MCL cells following PLK1 downregulation. Parental and therapy-resistant MCL cells treated with or without BI2536 inhibitor of PLK1 were evaluated for the presence of apoptotic bodies using cytomorphology. The rows from top to bottom consist of GP, GRK, GRL, and GRR. The left column consists of control- (DMSO-) treated cells and the right column consists of cells that have had PLK1 knocked down with BI2536. These observations were examined 48 hours after treatment at 40x magnification using a light microscopy.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.